Navacaprant

DB16068InvestigationalSmall molecule

BTRX-335140 is under investigation in clinical trial NCT04221230 (Study in Major Depressive Disorder With BTRX-335140 vs Placebo).

Mechanism: Pharmacologically active on Kappa-type opioid receptor
Curator reviewed
Formula / weight: C₂₅H₃₂FN₅O₂ · 453.562 g/mol (avg)
Code names: BTRX-335140 · CYM-53093 · NMRA-335140

Resolves to

Compound

Structure

InChIKeyCQOJHAJWCDJEAT-UHFFFAOYSA-NSMILESCCC1=CC(F)=C2N=C(N3CCC(CC3)NC3CCOCC3)C(C3=NC(C)=NO3)=C(C)C2=C1

Targets

What you can answer from here — as of September 16, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Navacaprant, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.